Health Care - Health Care Technology & Distribution: 2011 First

Lisa Gill repeats in first place. The J.P. Morgan analyst pounded the table on Omnicare in December

Lisa Gill J.P. Morgan The buy side says: “Lisa is always at the top of her game.”

Lisa Gill repeats in first place. The J.P. Morgan analyst pounded the table on Omnicare in December, at $22.93, when the Covington, Kentucky–based distributor of pharmaceuticals and health services to long-term care facilities announced that John Figueroa would succeed Joel Gemunder as CEO, effective January 1. (Gemunder had retired five months earlier; James Shelton had served as interim CEO while the company searched for Gemunder’s successor.) Gill, 42, believed that the Street would respond favorably to the appointment of Figueroa, who had been president of San Francisco–based McKesson Corp.’s U.S. pharmaceuticals unit. She was right. Omnicare shares hit a 52-week high of $32.97 in July before being pulled down by market turmoil; they closed at $29.71 late in August, for a 29.6 percent gain that beat the broad market — which was flat over the period — but trailed the sector by 14.1 percentage points. “Lisa keeps us informed on the latest trends and what their impact will be, both in the short term and the long,” asserts one satisfied client. Adds another: “She is a tireless worker and very responsive — always accessible.”

Related